Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT06817356

Other · Phase 2 · Active, not recruiting

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

NCT06817356 · Sponsor: Eli Lilly and Company

What this trial means for you

This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Mazdutide, Placebo for alcohol use disorder.

Who can joinAll sexes, 21 Years – 65 Years
Healthy volunteersNo — diagnosis required
What you'd takeMazdutide, Placebo
Study length~18 months overall
Planned participants300
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Current AUD diagnosis as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria. Exclusion Criteria: * Have a history of significant active or unstable major depressive disorder, suicidal ideation, or other severe psychiatric disorder within the last 12 months. * Have initiated psychotherapy, changed the intensity of psychotherapy, or other nondrug therapies (for example, acupuncture or hypnosis) within 8 weeks prior to enrollment. * Have received any medication for AUD in the last 30 days including but not limited to, disulfiram, acamprosate, naltrexone, gabapentin, baclofen, or topiramate. * Other protocol-specific inclusion and exclusion criteria may apply.

Study sites by state

Arizona

  • Headlands Research - Scottsdale — Scottsdale

Arkansas

  • Woodland Resarch Northwest/ERG — Rogers

California

  • Ark Clinical Research - Fountain Valley — Fountain Valley
  • Synergy San Diego — Lemon Grove
  • Headlands Research-Artemis San Diego — San Diego

Florida

  • Research Centers of America ( Hollywood ) — Hollywood
  • K2 Medical Research - Maitland — Maitland
  • K2 Medical Research — Maitland
  • Clinical Neuroscience Solutions Inc — Orlando
  • Clinical Neuroscience Solutions, Inc. — Orlando
  • K2 Medical Research - Tampa — Tampa

Georgia

  • CenExel iResearch, LLC (CenExel iRA) — Decatur

Louisiana

  • DelRicht Research — Mandeville

Massachusetts

  • Adams Clinical — Watertown
  • Vitalix Clinical — Worcester

Nevada

  • Redbird Research LLC — Las Vegas

New York

  • Richmond Behavioral Associates — Staten Island
  • Ichor Research — Syracuse
  • Davis Clinical — The Bronx

Oregon

  • Summit Headlands — Portland

Rhode Island

  • Rhode Island Mood & Memory Research Institute — East Providence

South Carolina

  • Medical University of South Carolina — Charleston

Tennessee

  • Clinical Neuroscience Solutions Inc — Memphis

Texas

  • FutureSearch Trials of Dallas — Dallas
  • Dallas Clinical Research Center/Pillar Research — Richardson

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth